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Objective: Esophageal adenocarcinoma (EAC) continues to be a disease associated with high 
mortality. Among the factors leading to poor outcomes are innate resistance to currently available 
therapies, advanced stage at diagnosis, and complex biology. Platinum and ionizing radiation 
form the backbone of treatment for the majority of patients with EAC. Of the multiple processes 
involved in response to platinum chemotherapy or ionizing radiation, deoxyribonucleic acid (DNA) 
repair has been a major player in cancer sensitivity to these agents. DNA repair defects have been 
described in various malignancies. The purpose of this study was to determine whether alterations 
in DNA repair are present in EAC compared with normal gastroesophageal tissues.
Methods: We analyzed the expression of genes involved in homologous recombination (HR), 
nonhomologous end-joining, and nucleotide excision repair (NER) pathways in 12 EAC tumor 
samples with their matched normal counterparts. These pathways were chosen because they are 
the main pathways involved in the repair of platinum- or ionizing-radiation-induced damage. In 
addition, abnormalities in these pathways have not been well characterized in EAC.
Results: We identified increased expression of at least one HR gene in eight of the EAC tumor 
samples. Alterations in the expression of EME1, a structure-specific endonuclease involved in 
HR, were the most prevalent, with messenger (m)RNA overexpression in six of the EAC samples. 
In addition, all EAC samples revealed decreased expression of at least one of numerous NER 
genes  including XPC, XPA, DDB2, XPF, and XPG.
Conclusion: Our study identified DNA repair dysregulation in EAC involving two critical 
pathways, HR and NER, and is the first demonstration of EME1 upregulation in any cancer. 
These DNA repair abnormalities have the potential to affect a number of processes such as 
genomic instability and therapy response, and the consequences of these defects deserve further 
study in EAC.
Keywords: esophageal adenocarcinoma, DNA repair, MUS81/EME1
Introduction
Esophageal cancer accounts for 4% of cancer deaths in the United States and is the 
sixth leading cause of cancer deaths among men. Esophageal adenocarcinoma (EAC) 
incidence has steadily increased during the last 2 decades.1 In 2013, 17,990 new EAC 
cases will be diagnosed, and the majority of these individuals have or will succumb 
to the disease.2 The rise in the incidence of esophageal cancer is accompanied by 
a change in the dominant histology of the disease from squamous cell carcinoma 
of the esophagus to adenocarcinomas mostly diagnosed in the distal esophagus or 
gastroesophageal junction. A major risk factor for EAC is chronic gastroesophageal 
reflux disease, which can lead to Barrett’s metaplasia, a precursor lesion for EAC.3 
Progression from metaplasia to adenocarcinoma is thought to be mediated by the 
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development of low-grade followed by high-grade dysplasia 
(more recently coined intraepithelial neoplasia), yet these 
histologic abnormalities do not uniformly precede EAC 
development in all patients.4
It has been suggested that all cancers are expected to dis-
play a defect in deoxyribonucleic acid (DNA) repair facilitat-
ing the accumulation of multiple mutations, which is a shared 
characteristic of all cancers.5 DNA repair defects characterizing 
a number of malignancies are being increasingly identified. For 
example, homologous recombination (HR) defects were noted 
in 50% of high-grade serous ovarian tumors.6 Nucleotide exci-
sion repair (NER) deficiency has been previously described in 
sporadic stage 1 breast cancers, testicular cancers, and lung 
cancers and has been linked to carcinogenesis and genomic 
instability.7–9 Ataxia telangiectasia mutated deficiency has been 
found in mantle cell lymphomas and gastric cancers.10,11
Multiple studies have shown that acid induces DNA damage 
in the esophagus, and multiple culprits leading to the damage 
have been described, including nitric oxide, bile acids present 
in duodenal reflux, and low pH.12–14 DNA repair pathways 
involved in the response to damage induced by these agents 
have not been fully characterized in EAC. Exploring DNA 
repair abnormalities in esophageal cancer has largely focused 
on the analysis of DNA repair polymorphisms and their associa-
tion with cancer susceptibility or therapy response.15 RAD51, 
an HR gene, was recently shown to be overexpressed in EAC 
and was associated with increased genomic instability. Little 
is known about the expression of other HR genes in addition 
to NER and nonhomologous end-joining (NHEJ) pathways in 
EAC. This is the focus of this article.
In this study, we analyzed the DNA repair transcript 
expression in 12 EAC tumor samples and individually 
matched normal gastroesophageal tissue. We focused on 
the HR, NHEJ, and NER pathways, as these are the most 
relevant to the therapies used in the clinic in the treatment of 
EAC because of their major role in repair of cisplatin- and/or 
ionizing-radiation-induced DNA damage. Our data highlight 
a number of DNA repair alterations that can have a critical 
effect on both EAC biology and DNA repair.
Materials and methods
Patients and samples
Primary EAC tumor samples and paired normal gastroeso-
phageal tissue of 12 patients who had not received prior che-
motherapy or radiation and who underwent esophagectomy 
at the Indiana University Hospital, Division of Cardiothoracic 
Surgery, were procured from the Indiana University Melvin 
and Bren Simon Cancer Center Tissue procurement facility 
through an institutional review board-approved protocol. All 
tumor samples originating from the gastroesophageal area had 
been snap-frozen immediately on resection in liquid nitrogen 
and stored until the time of analysis. Consistent with the epi-
demiology of EAC, all patients except one were men (n=11). 
The age of the patients ranged from 48 to 83 years, with a 
median of 74.5 years. Histologic examination was performed 
by an experienced pathologist on the formalin-fixed paraffin 
embedded (FFPE) blocks of both normal gastroesophageal 
and EAC samples to confirm the histology was accurate. Only 
EAC samples with 70% or more tumors were included in the 
analysis. Tumor note metastasis (TNM) stage was available for 
11 patients, and stage distribution was as follows: one patient 
had stage 1A carcinoma, four patients had stage 2B disease, 
five patients were stage 3A, and one patient had stage 3C 
disease. Patient characteristics are outlined in Table 1.
rna extraction and complementary 
Dna synthesis
Total RNA was isolated from 100 mg tissue samples using 
Trizol (Life Technologies, Carlsbad, CA, USA) and using 
an RNeasy minikit (Qiagen, Hilden, Germany) per manu-
facturer’s instructions. A nanodrop spectrophotometer was 
used to determine the quantity of RNA. Complementary (c)
DNA was generated using a High Capacity RNA-to-cDNA 
Kit (Life  Technologies, Carlsbad, CA, USA).
Transcript expression measurement 
by quantitative reverse transcription 
polymerase chain reaction
The expression levels of 16 reference genes were 
measured using the Taqman endogenous control array 
from ABI (catalog no 4367563; Applied Biosystems, 
Grand Island, NY, USA) to determine the most stably 
expressed gene between EAC samples and their matched 
Table 1 Characteristics of the patients who were included in 
the analysis
Patient Age (years) TNM stage Grade
1 74 T3n0 Poorly differentiated
2 83 T3n1 Moderately differentiated
3 79 T3n1 Poorly differentiated
4 63 T3n1 Poorly differentiated
5 71 T2n1 Poorly differentiated
6 (female) 48 T1n0 Poorly differentiated
7 65 Unavailable Unavailable
8 77 T3n0 Poorly differentiated
9 73 T3n1 Moderately differentiated
10 67 T4n1 Moderately differentiated
11 80 T3n0 Poorly differentiated
12 75 T3n1 Poorly differentiated
Abbreviation: TnM, tumor note metastasis.
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normal tissue (Figure S1). Seven samples (four tumors 
and three normal) were included in the endogenous con-
trol assay selection. Validated gene primer/probe sets for 
each gene of interest were purchased from ABI. Taqman 
reactions were analyzed using ABI’s 7900HT system. For 
each target gene, fold change in expression levels between 
normal and tumor sample was evaluated using ABI’s ∆∆CT 
Relative  Quantification methodology. Data were normal-
ized to the housekeeping gene GUSB (glucuronidase, beta) 
(Hs99999908_m1), and each tumor sample was calibrated 
to its normal matched control. Results presented are the 
average of two quantitative reverse transcription poly-
merase chain reaction (qRT-PCR) analyses with triplicate 
Taqman assays per RNA sample set. Genes analyzed and 
assays used are outlined in Table 2.
statistical analysis
Statistical analysis was performed using a paired Student’s 
two-tailed t-test (SigmaStat, Systat, Point Richmond, CA, 
USA). Differences between groups at P#0.05 were consid-
ered statistically significant.
immunohistochemistry
FFPE tissue sections corresponding to the EAC tumor 
samples were available for nine of the 12 samples. Immu-
nohistochemistry (IHC) was performed with the assistance 
of the IHC pathology laboratory at Indiana University. FFPE 
blocks were cut into 4 mm thick sections and collected on 
charged slides, and immunostaining was performed using 
the Autostainer Plus platform from Dako (Carpinteria, CA, 
USA). Slides were heated at 65°C for 30 minutes, deparaf-
finized with xylene, and rehydrated with graded alcohol. 
Endogenous peroxidase activity was blocked using 3% per-
oxidase blocking reagent (Dako K8002) for 5 minutes. Anti-
gen retrieval was performed by immersing sections in Dako’s 
PT module filled with FLEX Target Retrieval Solution, low 
pH (K800521), for 20 minutes. Sections were incubated for 
60 minutes with a 1:10 dilution of EME1 primary antibody 
(MTA31 7h2/1) from Santa Cruz Biotechnology (Dallas, TX, 
USA; sc-53275). Detection was performed using an Envi-
sion FLEX+ mouse kit from Dako. Normal uterine tissue 
was used as a positive control to optimize IHC conditions. 
All sections were examined by a surgical pathologist who 
confirmed the histology of normal/nonneoplastic esophageal 
tissue and EAC samples by reviewing hematoxylin and eosin 
sections. IHC staining for EME1 was scored on the basis 
of the intensity of nuclear staining (0, absent; 1, faint; 2, 
moderate; and 3, strong staining) and the extent of staining 
(0, 0%; 1, 1%–10%; 2, 10%–50%; and 3, .50% of tumor 
cells staining).
Western blot
Western blots were used to ensure specificity of the primary 
EME1 antibody, as this is the first report of the assessment 
of EME1 expression by IHC. HeLa cell, WI-38 (normal 
lung fibroblasts), and SK-GT4 (esophageal adenocar-
cinoma) cell line extracts were prepared as previously 
described.16 Protein concentration was determined using 
the Bio-Rad protein assay system (Bio-Rad Laboratories, 
Hercules, CA, USA) with bovine serum albumin standards. 
Forty micrograms of protein were loaded onto sodium 
dodecyl sulfate polyacrylamide gel electrophoresis, and 
after electrophoresis, proteins were transferred to poly-
vinylidene difluoride membranes. EME1 protein was 
detected using EME1 antibody (MTA31 7h2/1) at a 1:1000 
ratio, with secondary immunoglobulin (Ig)G horseradish 
peroxidase anti-mouse antibody (sc-2005, Santa Cruz) at 
a 1:4000 dilution.
Table 2 summary of Dna repair genes analyzed with their 
average fold changes and P-values
Pathway 
and gene 
symbol
Assay Average 
fold 
change
P-value Number of 
tumors with 
alterations
nucleotide excision repair
 XPA hs00166045_m1 0.48 0.0004* 12↓
 DDB1 hs00172410_m1 0.92 0.207 5↓
 DDB2 hs03044953_m1 0.75 0.0435* 8↓
 ERCC1 hs01012158_m1 0.76 0.0644 9↓
 ERCC2 hs00361161_m1 1.15 0.162 2↓
 ERCC3 hs01554450_m1 1.08 0.478 1↓
 XPF hs00193342_m1 0.710 0.004* 7↓
 XPG hs00164482_m1 0.715 0.039* 10↓
 XPC hs01104206_m1 0.633 0.009* 9↓
 RPA1 hs00161419_m1 0.900 0.234 6↓
 RPA2 hs00358315_m1 0.996 0.535 5↓
homologous recombination
 RAD51 hs00153418_m1 3.039 0.073 5↑
 RAD52 hs00172536_m1 1.218 0.254 2↑
 BRCA1 hs01556193_m1 1.867 0.187 5↑
 BRCA2 hs00609073_m1 1.867 0.137 5↑
 EME1 hs00385890_m1 2.971 0.007* 6↑
 MUS81 hs00228383_m1 0.833 0.457 4↓
nonhomologous end-joining
 Artemis hs01052780_m1 0.98 0.127 6↓
 DNAPK hs01016093_m1 1.49 0.485 2↓
 XRCC5 hs00221707_m1 1.00 0.602 5↓
 XRCC6 hs01922652_g1 0.86 0.267 4↓
 ATM hs01112307_m1 0.98 0.467 5↓
 ATR hs00354807_m1 1.37 0.652 2↓
 Ligase IV hs00172455_m1 1.28 0.678 3↓
Note: *Statistically significant genes, P#0.05.
Abbreviation: Dna, deoxyribonucleic acid.
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Oncomine database search
The Oncomine Cancer Profiling Database version 4.4.3, 
September 2012 data release (http://www.oncomine.org; 
Life Technologies, Carlsbad, CA, USA), was used to profile 
the gene EME1. Expression data and statistics were obtained 
directly through the Oncomine 4.4.3 software.
Results
eaC shows messenger rna 
overexpression of hr genes
Defects in a number of HR genes have been described in 
solid organ malignancies and have been shown to mediate 
sensitivity to a variety of chemotherapy agents including 
platinum, crosslinking agents, and poly(ADP-ribose) poly-
merase inhibitors.17–19 We initiated our work by screening 16 
endogenous housekeeping genes to determine the optimal 
endogenous control and identified GUSB as an excellent 
housekeeping gene with small differences in expression 
between tumor and normal tissues (Figure S1). All genes of 
interest were therefore normalized to GUSB transcript levels, 
and each tumor sample was compared with its matched nor-
mal sample. Eight of the 12 EACs showed messenger (m)
RNA overexpression of at least one of the HR genes, includ-
ing RAD51, RAD52, BRCA1, BRCA2, and EME1 (twofold 
cutoff or greater; Figure 1). EME1 was overexpressed in six 
of the 12 EACs, and the difference in expression was statis-
tically significant compared with normal tissue (P,0.001). 
Three of these tumor samples showed greater than fourfold 
EME1 mRNA overexpression (Figure 2).
The MUS81/EME1 protein complex is an endonuclease in 
the HR pathway with cleaving DNA intermediates as its main 
function. It plays an important role in maintaining genomic integ-
rity, yet its role in human disease and cancer is still undefined. 
As EME1 is present in complex with MUS81, we analyzed 
mRNA expression of MUS81 in the EAC samples and found 
that four tumor samples showed underexpression of MUS81 
when compared with a matched normal sample. RAD51 over-
expression approached statistical significance with a threefold 
change in EAC samples compared with normal counterparts. 
NHEJ genes evaluated showed a slight reduction in transcript 
expression in a few EAC samples when compared with normal 
counterparts, but none of them were statistically significant (Table 
2). Three of the patients had two samples from separate areas 
of the tumor available, and with the recent data revealing tumor 
heterogeneity in drug target expression and genomic differences 
within the same renal cell carcinoma sample, we were interested 
in whether we would be able to identify the heterogeneity of 
EME1 expression in different areas of the tumor.20 Transcript 
expression of the HR genes was reproducible between these 
biological duplicates (Table S1), suggesting EAC may not be as 
heterogeneous as renal cell carcinoma. We observed that all HR 
genes followed similar patterns in each tumor sample, where the 
majority of them either showed increased transcript expression 
or no change. Table 2 outlines genes evaluated in this analysis, 
along with fold change results.
eMe1 overexpression in eaC by ihC
As this is the first published report of EME1 upregulation in 
cancer, we were interested in assessing whether changes in 
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Figure 1 Quantitative reverse transcription polymerase chain reaction analyses of 
messenger (m)rna expression changes of homologous recombination genes. Data 
shown are the average of two separate quantitative reverse transcription polymerase 
chain reaction assays. genes of interest were normalized to GUSB transcript levels 
and are presented as fold changes relative to normal matched samples. EME1 
transcripts are increased in eaC samples.
Notes: *statistically significant results with P-value # 0.05.
Abbreviations: seM, standard error of the mean; eaC, esophageal adenocarcinoma.
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Figure 2 EME1 messenger (m)rna expression in individual esophageal 
adenocarcinoma samples, showing three tumor samples display more than fourfold 
overexpression of EME1.
Note: Dotted line refers to fold change of 1.
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the mRNA expression of MUS81/EME1 are accompanied 
by changes in its protein expression. Therefore, EME1 IHC 
was performed on FFPE sections corresponding to the fresh 
frozen samples analyzed by qRT-PCR for mRNA expression. 
Western blot assessment confirmed that the commercially 
available EME1 antibody used in these analyses did not 
show cross-reactivity and was highly specific for EME1, 
showing one dominant band at the expected size of 65 kDa 
noted in the HeLa and SK-GT4 cell lines, both of which 
represent positive controls (Figure S2). The WI-38 cell line, 
in contrast, does not display increased expression of EME1 
with a weaker band observed.
Normal uterine tissue was used as a control to optimize IHC 
conditions and showed an appropriate nuclear staining pattern 
of EME1 (Figure 3, insert). IHC analysis revealed that EME1 
was overexpressed at varying intensities in nine of nine tumor 
samples available for testing compared with normal tissues 
(Figure 3). Of note, EME1 staining intensity was noticeably 
less evident in the less-differentiated areas of the tumor, but 
the significance of this observation is unclear. Of note, gene 
and protein expression of EME1 did not necessarily correlate, 
as adenocarcinoma samples numbered 1, 2, and 11 showed 
less than twofold increase in EME1 mRNA expression but 
moderately increased EME1 IHC staining, and tumor sample 
10 had intense IHC staining that was not associated with any 
change in EME1 mRNA expression (Table S2).
eaCs display defects in ner
The NER pathway plays a significant role in repairing a 
variety of DNA lesions, including those resulting from 
ultraviolet radiation, chemotherapy agents, and mutagens.21 
Our analysis of the NER pathway showed that each of the 
12 tumor samples displayed an abnormality in transcript 
expression of at least one of the eleven NER genes analyzed 
(Table 2). XPC, XPA, DDB2, XPF, and XPG genes were 
statistically significantly underexpressed in EACs compared 
with normal samples (Table 2). XPA was underexpressed in all 
12 EAC samples, with fold changes in the range of 0.2 to 0.7, 
and this was statistically significant across all samples. This 
finding is consistent with the increased incidence of cancer 
in patients with xeroderma pigmentosum.22 The observation 
of NER deficiency in all EAC samples analyzed is extremely 
intriguing, especially with the role of this pathway in repair 
of DNA damage resulting from various sources.
Underexpression of NER components has been tied to 
poor prognosis in cancer, with clinical data suggesting it is 
more likely observed in higher stages of cancer as compared 
with earlier stages.23 As only one patient had stage 1 disease 
and still displayed decreased expression of NER components, 
it is unclear whether alterations in NER expression are more 
frequently encountered in more advanced EAC disease stages. 
It is potentially possible, however, that underexpression of 
NER in EAC contributes to its unfavorable prognosis.
EME1 is overexpressed in a number  
of cancers
EME1 overexpression noted in EAC in this study has not 
been previously described. In fact, EME1 overexpression 
has not been published in any cancer. This led us to con-
duct a search of the Oncomine gene expression database to 
evaluate whether other tumors overexpress EME1, and we 
chose a twofold change as threshold. This search showed that 
EME1 is overexpressed in head and neck, breast, and central 
nervous system tumors when compared with normal tissues. 
In addition, in one data set, papillary renal cell carcinoma and 
lymphoma each displayed mRNA overexpression of EME1 
(Table 3). There are a limited number of data sets for EAC in 
the Oncomine database, but our search did show EME1 was 
overexpressed in a portion of EACs compared with normal 
esophageal tissue in the Kim Esophagus data set. EME1 
seemed to be more highly expressed in our EAC samples 
when compared with data sets of other tumors reported in 
Oncomine, where the fold change was between 2 and 3. This 
observation might suggest that EME1 upregulation in EAC 
is unique, possibly as a response to acid damage.
Discussion
Multiple studies have highlighted genetic alterations in EAC, 
revealing mutations in the frequently mutated genes such 
as TP53 and PIK3CA, as well as less common mutations in 
SPG20, TLR4, ELMO1, and DOCK2.24,25 Limited data exist 
describing the DNA repair alterations present in EAC and 
with the fundamental role of chemotherapy and radiation in 
this disease, understanding those alterations has the potential 
Figure 3 eMe1 immunohistochemistry in gastroesophageal junction adenocarcinoma. 
(A) Well-differentiated gastroesophageal junction adenocarcinoma shows uniform 
strong nuclear staining pattern with eMe1 (250×). (B) eMe1 staining intensity 
was noticeably less in the less differentiated areas (500×). note the nuclear 
immunoreactivity for eMe1 in a control of benign endometrial stroma (inset).
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of further refining therapies and improving patient outcomes. 
In this study, we performed gene expression analysis of a 
focused group of DNA repair genes in EAC samples aris-
ing in the gastroesophageal junction area. The genes were 
carefully selected because of their involvement in the repair 
of damage induced by platinum or ionizing radiation in 
addition to existing data showing alterations in these genes 
in other malignancies. Our findings highlight a number of 
important observations including NER deficiency and HR 
overexpression in EAC.
Our analysis of 12 EAC samples shows that alterations in 
transcript expression of at least one NER gene are detected 
in all tumor samples, with XPC, XPA, DDB2, XPF, and XPG 
showing significant underexpression in tumors compared 
with their normal counterparts. Defective NER, through 
reduced expression of some of its components, especially 
XPA and ERCC1, has been postulated to be one of the main 
mechanisms of hypersensitivity of testicular cancer, includ-
ing in the metastatic stage to cisplatin therapy.26 There is an 
abundance of data demonstrating the connection between 
platinum resistance and NER function. XPA is an essential 
NER component and a rate-limiting factor in excision repair, 
and its decreased expression in all EAC samples evalu-
ated would suggest potential EAC sensitivity to cisplatin. 
However, clinical data are not consistent with that, as cis-
platin has modest activity in EAC and, as a single agent, 
has response rates of only 20%.27 The patients included in 
this analysis were not candidates for chemotherapy, and we 
are therefore unable to assess the effect of NER alterations via 
underexpression of XPA on their response to platinum-based 
therapy. However, on the basis of outcomes of patients with 
T3N1 EAC (the same stage as nine of 12 patients included 
in this analysis), estimated cure rates with the combination 
of platinum-based chemotherapy, radiation, and surgery are 
only 50%.28 These observations highlight the complexity of 
predicting response to platinum, which is orchestrated by 
multiple steps and proteins in the NER pathway in addition to 
other pathways such as HR playing a role, making it doubtful 
that the expression of a single DNA repair factor will dictate 
response to platinum.
Another finding in our analysis is that two thirds of EACs 
display increased expression of at least one of the HR genes 
analyzed, specifically BRCA1, BRCA2, RAD51, RAD52, and 
EME1. The HR pathway is mainly involved in the repair 
of DNA double strand breaks, yet consistently, HR defects 
have been shown to increase sensitivity to a wide variety 
of chemotherapy agents, including cisplatin.29 This more 
general effect of HR on therapy response could be related to 
the many proteins and subpathways involved in HR. The HR 
pathway is critical for the maintenance of genomic integrity, 
and further studies are needed to assess the consequences of 
upregulation of HR in EAC described here on the genomic 
instability noted in EAC. We have demonstrated no change 
in expression of the NHEJ genes evaluated; however, mRNA 
expression alone does not reflect the function of the NHEJ 
pathway in EAC. Both NHEJ and HR activity are regulated 
by protein interactions and posttranslational modifications, 
rather than transcription alone. The efficiency of NHEJ 
renders it less affected by transcription alone, and therefore, 
normal NHEJ gene expression does not necessarily mean 
normal function. Potential limitations of our study include 
the relatively small sample size.
Of the genes analyzed in this study, EME1, a component 
of the structure-specific endonuclease complex MUS81/
EME1, demonstrated the most frequent and statistically 
significant overexpression in EAC. EME1 shows increased 
transcript expression in 50% of EACs, with three tumor 
samples showing more than fourfold overexpression. In 
addition, EME1 protein expression is increased at varying 
intensities when analyzed by IHC in all EAC samples. Our 
study illustrates that although EME1 shows increased expres-
sion in EAC, its partner MUS81 showed either decreased 
Table 3 summary of Oncomine database search results of 
tumors with increased EME1 expression
Data set and  
cancer type
Number  
of samples
EME1 
expression 
fold change
P-value
French brain
  anaplastic  
oligoastrocytoma
33 2.615 8.5e-5
 Oligodendroglioma 33 2.3 8.24e-7
Murat brain
 glioblastoma 84 2.968 1.31e-7
richardson breast 2
 Ductal carcinoma 47 2.770 2.62e-9
TCga breast
 invasive ductal carcinoma 47 2.165 2.08e-27
 invasive lobular carcinoma 47 2.071 1.71e-8
Pyeon multicarcinoma
 Tonsillar carcinoma 84 2.162 4.28e-5
Ye head-neck
  Tongue squamous  
cell carcinoma
38 2.172 3.02e-6
TCga renal
  Papillary renal cell 
carcinoma
88 2.380 3.06e-7
Compagno lymphoma
  Diffuse large B cell 
lymphoma
136 2.459 1.50e-14
Note: Data available from: http://www.oncomine.org.34
Abbreviation: TCga, the cancer genome atlas.
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or unchanged mRNA expression. We are unaware of other 
reports evaluating the mRNA expression of both components 
of the MUS81/EME1 complex, but in another study, corre-
lation patterns of EME1 and MUS81 protein levels in vitro 
varied according to the cell lines analyzed.30 In addition, our 
data demonstrate that EME1 mRNA levels do not correlate 
with the protein expression absolutely (Table S1). These 
observations lead to a number of possibilities, including 
increased EME1 protein stability or posttranscriptional 
regulation of EME1 in some tumors.
A variety of biochemical and structural aspects of the 
MUS81/EME1 complex have been elucidated during the last 
decade, but its role in carcinogenesis remains to be defined. 
MUS81/EME1’s contribution to the recovery of stalled rep-
lication forks, a crucial step in preserving genome stability, 
suggests MUS81/EME1 defects would possibly mediate 
genomic instability, a bona fide hallmark of cancer.31,32 
This is supported by a number of observations including 
the associated increase of spontaneous gross chromosomal 
rearrangements in the setting of defective MUS81 or EME1.33 
Our search of the Oncomine Database showed that increased 
EME1 mRNA overexpression is not limited to EAC, as a 
number of malignancies display two- to threefold increased 
expression of EME1 (Table 3).
In conclusion, our study highlights a number of altera-
tions in the DNA repair expression profile of EACs, includ-
ing NER deficiency, HR upregulation, and the novel finding 
of increased expression of EME1. These defects possibly 
contribute to the genomic instability of EAC and potentially 
mediate resistance to chemotherapy and radiation that remains 
a challenge in caring for these patients. Discovering the impli-
cations of DNA repair abnormalities in EAC carcinogenesis 
and therapy response has the potential to improve outcomes 
of EAC. We are currently pursuing further studies to dissect 
the role of EME1 overexpression in EAC pathogenesis.
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Figure S1 Taqman endogenous control assay used to determine the optimal housekeeping gene. X axis shows samples used, Y axis showed Ct values of each gene.
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Figure S2 Western blot analysis evaluating eMe1 primary antibody in heLa, Wi-38, and sK-gT4 cell extracts. One major band can be seen at expected size of 65 kDa in 
both heLa and sK-gT4 cell extracts. The band is present but much weaker in the Wi-38 cell line.
Abbreviation: gaPDh, glyceraldehyde 3-phosphate dehydrogenase.
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Table S1 summary of messenger rna expression of homologous 
recombination genes in three tumor samples and their biological 
duplicates
Gene and  
tumor number
Average  
fold change
Biological  
replicate
Average 
fold change
EME1
 4 4.5 T4 replicate 5.7
 3 5.9 T3 replicate 3.3
 2 1.9 T2 replicate 0.9
RAD51
 4 7.6 T4 replicate 12.8
 3 1.5 T3 replicate 1.5
 2 0.5 T2 replicate 0.5
RAD52
 4 0.7 T4 replicate 0.5
 3 2.3 T3 replicate 2.1
 2 0.4 T2 replicate 0.4
BRCA1
 4 3.1 T4 replicate 1.5
 3 5.2 T3 replicate 2.9
 2 0.7 T2 replicate 0.5
BRCA2
 4 4.2 T4 replicate 5.4
 3 3.7 T3 replicate 1.7
 2 0.8 T2 replicate 0.8
MUS81
 4 0.8 T4 replicate 0.4
 3 1.0 T3 replicate 1.0
 2 0.3 T2 replicate 0.1
Table S2 summary of results of EME1 messenger (m)rna and 
eMe1 protein expression in each of the individual esophageal 
adenocarcinoma samples
Sample  
number
EME1 immunohistochemistry  
score
EME1 mRNA 
fold change
1 2+2+ 1.8
2 2+2+ 1.9
3 2+3+ 5.9
4 2+2+ 4.5
5 Block not available 1.4
6 Block not available 1.1
7 3+3+ 2.3
8 Block not available 2.5
9 2+3+ 2.6
10 3+3+ 1.1
11 3+2+ 1.8
12 2+3+ 8.2
